7 recruiting, 5 completed, 2 active not recruiting. 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Recruiting 7, Completed 5, Active not recruiting 2 |
Follow iptacopan: new trials by email Literature Review of iptacopan trials Research Report on iptacopan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN iptacopan - Primary Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 31 | 2025-11-27 | 2026-09-09 |
| Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients LNP023 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 12 | 2025-10-28 | 2026-08-07 |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. Iptacopan, Matching Placebo - Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 146 | 2024-07-31 | 2026-08-12 |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-02-28 | 2026-04-29 |
| Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN Placebo, iptacopan - IC-MPGN | Phase 3 | Recruiting | Novartis Pharmaceuticals | 106 | 2023-10-02 | 2026-07-13 |
| Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. Iptacopan - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Novartis Pharmaceuticals | 52 | 2023-04-24 | 2026-01-13 |
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 34 | 2022-01-17 | 2026-08-07 |
| A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy LNP023 - Primary IgA Nephropathy | Phase 3 | Recruiting | Novartis Pharmaceuticals | 540 | 2021-09-20 | 2026-10-05 |
| Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Placebo, iptacopan - C3G | Phase 3 | Recruiting | Novartis Pharmaceuticals | 98 | 2021-07-28 | 2026-11-05 |
| Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria Iptacopan - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 208 | 2021-07-27 | 2026-08-07 |
| Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Iptacopan (LNP023) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Completed | Novartis Pharmaceuticals | 40 | 2021-07-19 | 2024-10-09 |
| Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment LNP023, Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Completed | Novartis Pharmaceuticals | 97 | 2021-01-25 | 2024-10-09 |
| Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients Placebo, LNP023 - IgA Nephropathy | Phase 3 | Completed | Novartis Pharmaceuticals | 517 | 2021-01-25 | 2026-11-04 |
| Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN LNP023 - C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase 3 | Recruiting | Novartis Pharmaceuticals | 225 | 2019-10-03 | 2026-08-07 |
Hemoglobinuria, Paroxysmal (5) · Anemia (4) · Proteinuria (4) · Glomerulonephritis, IGA (3) · Atypical Hemolytic Uremic Syndrome (2) · Thrombotic Microangiopathies (2) · Glomerulonephritis (1) · Glomerulonephritis, Membranoproliferative (1) · Myasthenia Gravis (1) · Renal Insufficiency, Chronic (1)
Germany (12) · Italy (12) · United States (12) · France (11) · Japan (11) · United Kingdom (11) · Brazil (10) · China (10) · Spain (10) · South Korea (9) · Czechia (8) · Netherlands (8) · Turkey (Türkiye) (8) · Argentina (7) · Israel (7)
PMID 40694294, PMID 38477987, PMID 40447351, PMID 35675911, PMID 37772889, PMID 37914086, PMID 38299639, PMID 39453772, PMID 41016405, PMID 41661687, PMID 41910396, PMID 42909451
2023 (3), 2018 (1), 2019 (1)